

Medical Policy



Title: Facet Joint Denervation

Related Policies:	▪ <i>Diagnosis and Treatment of Sacroiliac Joint Pain</i>
-------------------	---

Professional / Institutional
Original Effective Date: October 18, 2004 / July 1, 2005
Latest Review Date: January 5, 2026
Current Effective Date: January 15, 2021

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

Populations	Interventions	Comparators	Outcomes
Individuals: • With suspected facet joint pain	Interventions of interest are: • Diagnostic medial branch blocks	Comparators of interest are: • Clinical diagnosis	Relevant outcomes include: • Other test performance measures • Symptoms • Functional outcomes
Individuals: • With facet joint pain	Interventions of interest are: • Radiofrequency ablation	Comparators of interest are: • Intra-articular injection • Standard medical therapy	Relevant outcomes include: • Symptoms • Functional outcomes • Quality of life • Medication use
Individuals: • With facet joint pain	Interventions of interest are: • Therapeutic medial branch blocks • Alternative methods of denervation	Comparators of interest are: • Intra-articular injection • Standard medical therapy	Relevant outcomes include: • Symptoms • Functional outcomes • Quality of life • Medication use

DESCRIPTION

Facet denervation is used to treat neck and back pain originating in facet joints with degenerative changes. Diagnosis of facet joint pain is confirmed by response to nerve blocks. The goal of facet denervation is long-term pain relief. However, the nerves regenerate and, therefore, repeat procedures may be required.

OBJECTIVE

The objectives of this evidence review are to determine whether the use of (1) medial branch blocks to identify individuals with facet joint pain; (2) radiofrequency ablation to treat individuals with facet joint pain; and (3) therapeutic medial branch blocks or alternative methods of denervation to treat individuals with facet joint pain improves the net health outcome.

BACKGROUND**Facet Joint Denervation**

Percutaneous radiofrequency (RF) facet denervation is used to treat neck or back pain originating in facet joints with degenerative changes. Diagnosis of facet joint pain is confirmed by response to nerve blocks. Patients generally are sedated for the RF procedure. The goal of facet denervation is long-term pain relief. However, the nerves regenerate and, therefore, repeat procedures may be required.

Facet joint denervation is performed under local anesthetic and with fluoroscopic guidance. A needle or probe is directed to the median branch of the dorsal ganglion innervating the facet joint, where multiple thermal lesions are produced, typically by an RF generator. A variety of terms may be used to describe RF denervation (eg, rhizotomy, rhizolysis). In addition, the structures to which the RF energy is directed may be referred to as facet joint, facet nerves, medial nerve or branch, median nerve or branch, or dorsal root ganglion.

Alternative methods of denervation include pulsed RF, laser, chemodenervation, and cryoablation. Pulsed RF consists of short bursts of electric current of high voltage in the RF range but without heating the tissue enough to cause coagulation. RF is suggested as a possibly safer alternative to thermal RF facet denervation. Temperatures do not exceed 42°C at the probe tip versus temperatures in the 60°C range reached in thermal RF denervation, and tissues may cool between pulses. It is postulated that transmission across small unmyelinated nerve fibers is disrupted but not permanently damaged, while large myelinated fibers are not affected. With chemical denervation, injections with a diluted phenol solution, a chemical ablating agent, are injected into the facet joint nerve.

REGULATORY STATUS

A number of RF generators and probes have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. In 2005, the SInergy® (Kimberly Clark/Baylis), a water-cooled single-use probe, was cleared by the FDA, listing the Baylis Pain Management Probe as a predicate device. The intended use is with an RF generator to create RF lesions in nervous tissue. FDA product code: GXD.

POLICY

- A. Nonpulsed radiofrequency denervation of cervical facet joints (C2-3 and below) and lumbar facet joints is considered **medically necessary** when **ALL** of the following criteria are met:
 - 1. No prior posterior spinal fusion surgery in the vertebral level being treated; **AND**
 - 2. Disabling low back (lumbosacral) or neck (cervical) pain, suggestive of intrinsic facet joint origin as supported by history and physical; **AND**
 - 3. Pain has failed to respond to three (3) months of conservative management; **AND**
 - 4. There has been a successful trial of confirming medial branch blocks (see Policy Guidelines); **AND**
 - 5. If there has been a prior successful radiofrequency (RF) denervation, a minimum time of six (6) months has elapsed since prior RF nerve treatment.
- B. Radiofrequency denervation is considered **experimental / investigational** for the treatment of chronic spinal / back pain for all uses that do not meet the criteria listed above, including, but not limited to, the treatment of thoracic facet joint pain, or nerves innervating the SI joint.
- C. All other methods of denervation are considered **experimental / investigational** for the treatment of chronic spinal / back pain, including, but not limited to pulsed radiofrequency denervation, laser denervation, chemodenervation (e.g., alcohol, phenol, or high-concentration local anesthetics), and cryodenervation.
- D. Therapeutic medial branch blocks are considered **experimental / investigational**.
- E. If there has been a prior successful radiofrequency (RF) denervation, additional prognostic blocks at the same level may be considered **not medically necessary** to confirm the source of pain is from the same segmental level.

POLICY GUIDELINES

- A. A successful trial of controlled diagnostic medial branch blocks consists of 2 positive blocks performed on separate days, under fluoroscopic guidance, that have resulted in at least an 80% reduction in pain for the duration of the local anesthetic (no steroids or other drugs) used (e.g., 3 hours longer with bupivacaine than lidocaine).
- B. No therapeutic intra-articular injections (i.e., steroids, saline, or other substances) should be administered for a period of at least 4 weeks prior to the diagnostic medial branch block. The diagnostic blocks should involve the levels being considered for radiofrequency treatment and should not be conducted under intravenous sedation unless specifically indicated (e.g., the individual is unable to cooperate with the procedure). These diagnostic blocks should be targeted to the likely pain generator. Single level blocks lead to more precise diagnostic information, but multiple single level blocks require several visits and additional exposure to radiation.
- C. *Parallel Needle Placement.* In order to incorporate target nerves reliably, electrodes must be placed close and parallel to the nerve. Electrodes that touch the nerve will reliably

incorporate the nerve into the lesion they produce, even if the lesion is of minimal size, as proximity to the nerve is crucial. One method to ensure the target nerve is denervated is to place multiple lesions, in such a fashion as to ensure that a volume of tissue is coagulated that encompasses the entire volume in which the target nerve might lie.

Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

RATIONALE

This evidence review was created using searches of the PubMed database. The most recent literature update was performed through October 3, 2025.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

SUSPECTED FACET JOINT PAIN

Clinical Context and Test Purpose

The purpose of diagnostic medial branch blocks in individuals with suspected facet joint pain is to confirm a diagnosis and proceed to appropriate treatment.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with suspected facet joint pain.

Interventions

The test being considered is diagnostic medial branch blocks.

Comparators

The following practice is currently being used to diagnose facet joint pain: clinical diagnosis.

Outcomes

The general outcomes of interest are an accurate diagnosis of pain etiology, a reduction in symptoms and medication use, and improvements in functional outcomes.

Follow-up after a diagnostic medial branch block is short-term to assess response to the procedure.

Study Selection Criteria

For the evaluation of clinical validity of the test, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology.
- Included a suitable reference standard.
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

REVIEW OF EVIDENCE**Systematic Reviews**

Boswell et al (2015) reported on a systematic review evaluating the accuracy and utility of facet joint injections for the diagnosis of facet joint pain.¹ Coauthors included Manchikanti, who is the primary author on most of the studies included in the systematic review. Of the 13 studies on the diagnosis of lumbar facet joint pain that used a criterion standard of at least 75% pain relief, 11 were conducted by the same group of authors, and all 3 studies on the diagnosis of thoracic facet joint pain were conducted by the same group. Study quality was rated by reviewers who were not coauthors of the primary studies. Using the Quality Appraisal of Diagnostic Reliability checklist, evidence was rated as level I for controlled lumbar facet joint blocks, level II for cervical facet joint blocks, and level II for thoracic facet joint blocks. However, in none of the studies were raters blinded to clinical information or to the reference standard. In addition, there is no criterion standard test for the diagnosis of facet joint pain, which creates difficulties in determining test accuracy.

The Boswell et al (2015) review included 17 studies on lumbar facet joint pain that used controlled blocks with a diagnostic criterion of at least 75% pain relief. Prevalence was reported as 16% to 41%, with false-positive rates of 25% to 44%. For cervical facet joint pain, 11 controlled diagnostic studies were included, reporting a variable prevalence ranging from 36% to 67% and false-positive rates ranging from 27% to 63%. For thoracic facet joint pain, 3 studies used a criterion standard of 80% or higher pain relief, reporting prevalence rates ranging from 34% to 48% and false-positive rates ranging from 42% to 48%. The systematic review did not specify the reference standard used to determine the prevalence of false-positive rates. Four studies evaluated the influence of diagnostic blocks on therapeutic outcomes; 3 of them are described below.

Falco et al (2012) updated several systematic reviews on the diagnosis and treatment of facet joint pain.^{2,3,4,5} The authors found good evidence for diagnostic nerve blocks with at least 75% pain relief as the criterion standard but only limited to fair evidence for diagnostic nerve blocks with 50% to 74% pain relief.

Randomized Controlled Trials

Cohen et al (2010) reported a multicenter randomized cost-effectiveness trial comparing 0, 1, or 2 diagnostic blocks before lumbar facet radiofrequency (RF) denervation.⁶ Included in the trial were 151 patients with predominantly axial low back pain of 3 months or more in duration,

failure to respond to conservative therapy, paraspinal tenderness, and absence of focal neurologic signs or symptoms. Of the 51 patients who received RF denervation without undergoing diagnostic blocks, 17 (33%) obtained a successful outcome. Of the 16 (40%) patients who had a single diagnostic block followed by RF denervation, 8 (50%) of 16 were considered successful. Of the 14 (28%) patients who had RF denervation after 2 medial branch blocks, 11 (79%) of 14 were considered successful. Three patients were successfully treated after medial branch blocks alone.

Observational Studies

Cohen et al (2008) compared lumbar zygapophyseal joint RF denervation success rates between the conventional threshold ($\geq 50\%$ pain relief) and the more stringently proposed cutoff ($\geq 80\%$) in a retrospective multicenter study with 262 patients.⁷ A total of 145 patients had between 50% and 80% relief after medial branch block, and 117 obtained 80% or more relief. In the 50% or more group, success rates were 52% and 67% on pain relief and global perceived effect (GPE), respectively, after RF. Among those who had 80% or more relief from diagnostic blocks, 56% achieved at least 50% relief from RF, and 66% had a positive GPE. The study concluded that the more stringent pain relief criteria would be unlikely to improve success rates.

Pampati et al (2009) conducted an observational study of 152 patients diagnosed with lumbar facet pain using controlled diagnostic blocks.⁸ Of 1149 patients identified for interventional therapy, 491 patients were suspected of lumbar facet joint pain and received 1% lidocaine block. Of the 491 patients who received lidocaine, 261 were positive ($\geq 80\%$ reduction of pain and ability to perform previously painful movements lasting at least 2 hours) and underwent bupivacaine blocks. The 152 who responded positively to bupivacaine block were treated with RF neurotomy or medial branch blocks and were followed for 2 years. At 2-year follow-up, 136 (89%) of the 152 patients with a positive response to bupivacaine were considered to have lumbar facet joint pain based on pain relief and functional status improvement after facet joint intervention.

Manchikanti et al (2010) compared outcomes of 110 patients who underwent facet nerve blocks after meeting positive criteria of 50% pain relief and 2 years of follow-up.⁹ At the end of 1 year, the diagnosis of lumbar facet joint pain was confirmed (by sustained relief of pain and improved function) in 75% of patients in the group with 50% relief from diagnostic blocks versus 93% in the group with 80% relief. At 2 years, the diagnosis was sustained in 51% of patients in the group with 50% relief; the diagnosis was sustained in 89.5% of patients who reported 80% relief from diagnostic blocks.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

No RCTs were identified assessing the clinical utility of medial branch blocks to diagnose suspected facet joint pain.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity.

There is level I evidence supporting the use of medial branch blocks for diagnosing chronic lumbar facet joint pain and level II evidence for diagnosing cervical and thoracic facet joint pain. The evidence available supports a threshold of at least 75% to 80% pain relief to reduce the false-positive rate.

Section Summary: Detection of Facet Joint Pain With Medial Branch Blocks

For individuals who have suspected facet joint pain who receive diagnostic medial branch blocks, the evidence includes systematic reviews, a small randomized trial, and observational studies. There is considerable controversy about the role of these blocks, the number of positive blocks required, and the extent of pain relief obtained. Studies have reported the use of single or double blocks and at least 50% or 80% improvement in pain and function. This evidence has suggested that there are relatively few patients who exhibit pain relief following 2 nerve blocks, but that these select patients may have pain relief for several months following RF denervation. Other large series have reported the prevalence and false-positive rates following controlled diagnostic blocks, although there are issues with the reference standards used in these studies because there is no criterion standard for the diagnosis of facet joint pain. There is level I evidence for the use of medial branch blocks for diagnosing chronic lumbar facet joint pain and level II evidence for diagnosing cervical and thoracic facet joint pain. The evidence available supports a threshold of at least 75% to 80% pain relief to reduce the false-positive rate.

Diagnosed Facet Joint Pain

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The RCT is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

FACET JOINT DENERVATION WITH RADIOFREQUENCY ABLATION

Clinical Context and Therapy Purpose

The purpose of radiofrequency ablation (RFA) in individuals who have facet joint pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with facet joint pain.

Interventions

The therapy being considered is RFA.

Comparators

The following therapies and practices are currently being used to treat confirmed facet joint pain: intra-articular injection and standard medical therapy.

Outcomes

The general outcomes of interest are reductions in symptoms and medication use, quality of life (QOL), and improvements in functional outcomes.

Follow-up after RFA or medial branch block may be required from 6 to 12 months to monitor for symptom recurrence and the need for additional treatments.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

REVIEW OF EVIDENCE**Systematic Reviews**

Li et al (2022) published a systematic review and meta-analysis of 10 RCTs (N=715) comparing various RF denervation interventions including conventional RF.¹⁰ Short-term (≤ 6 months) and long-term (12 months) visual analog scale (VAS) pain scores were evaluated in a network meta-analysis. Conventional RF improved pain compared with placebo in both the short (standardized mean difference [SMD], -1.58; 95% confidence interval [CI], -2.98 to -0.18) and long term (SMD, -4.90; 95% CI, -5.86 to -3.94).

In a systematic review and meta-analysis by Janapala et al (2021), 12 RCTs were identified evaluating the efficacy of lumbar RF neurotomy.¹¹ Studies were excluded from the analysis that included patients with acute causes of low back pain due to trauma, fracture, and malignancy. Four of the 12 studies in the meta-analysis are discussed below: Nath et al (2008)¹², Tekin et al

(2007)¹³, van Wijk et al (2005)¹⁴, and Lakemeier et al (2013).¹⁵ Patients across the 12 studies received 1 of the following interventions: RFA with a 22-gauge electrode, pulsed RF, medial branch conventional RF, medial branch cooled RFA, medial branch RF plus pentoxifylline or methylprednisolone injection, distal approach RF neurotomy, tunnel-vision approach RF neurotomy, RF frequency coagulation of joint capsule, endoscopic neurotomy, intra-articular lumbar steroid injection, or sham treatment. Each RCT included at least 6 months of follow-up, with 7 trials including active controls and 5 trials either sham or placebo control. Sample sizes included a range from 31 to 251 patients. Meta-analysis of pain relief of RF neurotomy versus sham control at 6 months and 12 months included 3 studies in the 6-month assessment (n=160) and 2 studies in the 12-month (n=291). At both timepoints, RF neurotomy was favored for improving VAS pain scores; however, differences were not statistically significant and were imprecise with wide confidence intervals (SMD at 6 months, 1.98, 95% CI, -0.50 to 4.47), and (SMD at 12 months, -0.22, 95% CI, -0.83 to 0.39). The interpretation of these findings is limited by high heterogeneity across studies ($I^2=95\%$ for 6-month data and $I^2=71\%$ for 12-month data), imprecision, risk of bias of individual included studies due to lack of blinding, and the lack of subgroup analyses of patients with predictors of success such as prior response to controlled medial branch blocks and the presence of tenderness over the facet joint.

A systematic review by Manchikanti et al (2015) identified 9 RCTs and comparative studies assessing RF denervation of lumbar facet joints.¹⁶ Sample sizes ranged from 31 to 100 patients. All studies but 1 showed a short- or long-term benefit of facet joint denervation. For short-term effectiveness (<6 months), the evidence was level I; for long-term effectiveness (≥ 6 months), the evidence was level II.

Randomized Controlled Trials

The largest study included in the review by Manchikanti et al (2015) compared facet joint injection with facet joint denervation in 100 patients (Civilek et al [2012]¹⁷). There were no sham controls, which limited interpretation of the results. In a double-blind RCT by Lakemeier et al (2013), RF facet joint denervation was compared with intra-articular steroid injections in 56 patients.¹⁵ Patients were selected first on magnetic resonance imaging findings of hypertrophy of the facet joints followed by a positive response to an intra-articular infiltration of the facet joints with anesthetics. A diagnostic double-block of the facet joint was not performed. At 6 months, there was no significant difference between the 2 groups, although it is not clear if the mean VAS scores were significantly improved in either group.

In an RCT, Nath et al (2008) evaluated 40 patients for the short- and intermediate-term effects of RF for lumbar facet pain.¹² To be enrolled in the trial, patients had to obtain at least 80% pain relief following controlled (3 positive separate) medial branch blocks. Screening medial branch blocks were performed in 376 patients; 115 were negative, 261 patients had greater than 80% relief of at least 1 component of their pain and proceeded to controlled blocks. Of the 261 patients, 45 had a negative response to controlled blocks, 105 had prolonged responses, and 71 lived too far away to participate or declined. The 40 patients remaining were randomly assigned, half to RF and half to sham treatment; all participated throughout the 6-month study. Pretreatment, the RF group had significantly more generalized pain, low back pain, and referred pain to the leg. Generalized pain on a VAS was reduced by 1.9 points (from 6.3 to 4.1) in the RF group and by 0.4 points (from 4.4 to 4.8) for placebo ($p=.02$). Back pain was reduced in the RF group by 2.1 points (from 5.98 to 3.88) and by 0.7 points (from 4.38 to 3.68) in the placebo group; between-group differences were significant. Patients receiving RF experienced

significantly more improvement in secondary measures of back and hip movement, QOL variables, the sacroiliac joint test, paravertebral tenderness, and tactile sensory deficit. The interpretation of this trial was limited by baseline differences between groups.

Van Wijk et al (2005) published a multicenter RCT that found no benefit of facet joint denervation.¹⁴ Inclusion criteria consisted of the following: continuous low back pain with or without radiating pain into the upper leg for more than 6 months; focal tenderness over the facet joints without sensory or motor deficits or without the ability to perform the positive straight leg raising test; no indication for low back surgery; and 50% or greater pain reduction 30 minutes after lidocaine block. Of 226 patients screened, 81 were randomized to RF (n=40) or sham (n=41) lesion treatment. Success was defined as a 50% or more reduction of median VAS back pain score without a reduction in daily activities and/or a rise in the analgesic intake or reduction of 25% or more. At 3 months, there was no difference between groups (27.5% of RF patients were successes vs 29.3% of sham patients). This trial used a single (uncontrolled) block, which is known to increase the false-positive rate.

Two RCTs published by Lord et al (1996) and van Eerd et al (2021) have evaluated RF for chronic cervical pain at the facet joints.^{18,19} In Lord et al (1996), patients with C2 to 3 zygapophyseal joint pain were excluded because treatment at this level is technically difficult. Twenty-four patients (of 54 screened) were randomized to RF or sham treatment.¹⁸ Six patients in the control group and 3 in the RF group had an immediate return of pain after the procedure. By 27 weeks, 1 patient in the control group and 7 in the RF group remained free of pain. The median time to return of pretreatment pain of greater than 50% was 263 days in the RF group and 8 days in the placebo group. Two patients in the active group—who had no relief of pain—were found to have pain from adjacent spinal segments. In van Eerd et al (2021), 76 patients with pain for ≥ 3 months and conservative management of their cervical pain were randomized to receive RF plus 3 bupivacaine injections or 3 bupivacaine injections alone. Patients with whiplash-associated pain were excluded from the study.¹⁹ For each patient, 3 cervical medial branches were denervated by the cervical facet joint level judged as painful on palpation. Follow-up at 6 months showed no clinically meaningful outcomes in numeric rating scale pain scores between treatment groups. Quality of life improvement, as measured by the bodily pain domain within the Rand 36-Item Health Survey, showed significant improvement at 6 months, with scores of 61.6 for RF versus 48.6 for no RF ($p=.01$). Patients with treatment success at 6 months, defined by a pain reduction of at least 30%, received follow-up at 48 months to assess long term effects. The median time to end of treatment success was 42 months in the RF group compared to 12 months with no RF ($p=.014$). At one year, the proportion of patients still reporting treatment effect was 0.9 (95% CI; 0.75 to 0.97) in the RF group compared to 0.41 (95% CI; 0.19 to 0.62) with no RF.

No controlled trials evaluating RF denervation in thoracic facet joints were identified.

Repeat Procedures

The literature primarily consists of small retrospective studies of repeat procedures after successful RF.^{20,21} A systematic review by Smuck et al (2012) evaluated 16 studies of repeated medial branch neurotomy for facet joint pain and found that repeated RF denervation was successful 33% to 85% of the time when the first procedure was successful.²² The estimated average duration of pain relief was 7 to 9 months after the first treatment and 11.6 months after a repeated lumbar procedure.

In 2 series, more than 80% of patients had greater than 50% relief from repeat RF treatment, and the mean duration of relief from subsequent RF treatments was comparable to initial treatments. In a report by Rambaransingh et al (2010), similar improvements in outcomes were observed following the first, second, or third RF treatments in a series of 73 patients who underwent repeat RF denervation for chronic neck or back pain.²³ The average duration of pain relief was 9.9 months after the first treatment and 10.5 months after the second treatment.

Section Summary: Facet Joint Denervation With Radiofrequency Ablation

For individuals who have facet joint pain who receive RFA, the evidence includes systematic reviews and RCTs. While the evidence is limited to RCTs with small sample sizes ($N \leq 251$), RF facet denervation appears to provide at least 50% pain relief in carefully selected patients. Diagnosis of facet joint pain is difficult. However, response to controlled medial branch blocks and the presence of tenderness over the facet joint appear to be reliable predictors of success. When RF facet denervation is successful, repeat treatments appear to have similar success rates and duration of pain relief. Thus, the data indicate that, in carefully selected individuals with lumbar or cervical facet joint pain, RF treatments can improve outcomes.

THERAPEUTIC MEDIAL BRANCH BLOCKS AND ALTERNATIVE METHODS OF DENERVATION

Clinical Context and Therapy Purpose

The purpose of therapeutic medial branch blocks or alternative methods of denervation in individuals who have facet joint pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with facet joint pain.

Interventions

The therapies being considered are therapeutic medial branch blocks and alternative methods of denervation.

Comparators

The following practices are currently being used to treat confirmed facet joint pain: intra-articular injection and standard medical therapy.

Outcomes

The general outcomes of interest are reductions in symptoms and medication use, QOL, and improvements in functional outcomes. Follow-up at 6 to 12 months is of interest to monitor outcomes.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;

- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

REVIEW OF EVIDENCE

Branch Blocks

Medial branch nerve blocks have been evaluated as a therapeutic intervention. However, no RCTs were identified that compared anesthetic nerve blocks with placebo injections. Placebo-controlled studies are important for treatments for which the primary outcome is a measurement of pain to account for the potential placebo effect of an intervention.

Systematic Reviews

The reviews by Falco et al (2012), discussed above, assessed the diagnosis and treatment of facet joint pain.^{2,3,5,4} Evidence for the use of therapeutic cervical medial branch blocks was fair, and evidence for therapeutic lumbar facet joint nerve blocks was rated as fair-to-good.

Randomized Controlled Trials

Three, 2010 double-blind RCTs were identified in the systematic review by Manchikanti et al (2015) that compared the therapeutic effect of medial branch blocks plus bupivacaine alone with bupivacaine and a steroid (betamethasone).^{24,25,26} Patients had a diagnosis of facet joint pain (cervical, thoracic, lumbar) with an 80% reduction in pain following 2 diagnostic anesthetic blocks of the medial branches. Patient outcomes were measured at 3, 6, 12, 18, and 24 months with a numeric rating scale for pain and the Oswestry Disability Index (ODI). Significant pain relief was considered to be a decrease of 50% or more on a numeric rating scale. Opioid intake and work status were also evaluated. The trials are described below.

Cervical

One of the randomized trials (Manchikanti et al [2010]) included 120 patients meeting the diagnostic criteria for cervical facet joint pain.²⁴ The 2 groups were further subdivided, with half in each group receiving sarracenia purpurea (Sarapin). Patients were followed at 3-month intervals, and the cervical medial branch blocks were repeated only when reported pain levels decreased to below 50%, with significant pain relief after the previous block. Injections were repeated an average of 5.7 times over a period of 2 years. Sarapin did not affect the outcome, and the data were reported only for the 2 main conditions. At 2-year follow-up, 85% of patients in the bupivacaine group and 93% of patients in the steroid group were reported to have significant pain relief, based on an intention-to-treat analysis. The average duration of pain relief with each procedure was 17 to 19 weeks. At least 50% improvement on the Neck Disability Index score was seen in 70% of patients in the bupivacaine group and 75% of patients in the bupivacaine plus steroid group. There was no significant change in opioid intake. There was a loss of 38% of the data for the 24-month evaluation. Sensitivity analysis using the last follow-up score, best-case scenario, and the worst-case scenario did not differ significantly.

Lumbar

A second double-blind, randomized trial by Manchikanti et al (2010) evaluated the efficacy of facet joint nerve blocks in 120 patients with chronic low back pain.²⁵ In addition to the 2 main

conditions, half the patients in each group received Sarapin. Sarapin did not affect the outcome and the data were reported only for the 2 main conditions. Patients received 5 to 6 treatments during the study. At a 2-year follow-up, significant pain relief ($\geq 50\%$) was observed in 85% of the patients treated with bupivacaine alone and 90% of the patients treated with bupivacaine plus steroid. The proportion of patients with significant functional status improvement ($\geq 40\%$ on the ODI) was 87% for bupivacaine and 88% for the control group. The average duration of pain relief with each procedure was 19 weeks. There was no significant change in opioid intake. Twenty-four-month results were missing for 20% of the subjects. Sensitivity analysis of numeric rating scale pain scores using the last follow-up score, best-case scenario, and the worst-case scenario did not differ significantly.

Thoracic

One year results were reported in 2010 and 2-year results in 2012 by Manchikanti et al from the randomized, double-blind trial evaluating the efficacy of thoracic medial branch blocks performed under fluoroscopy.^{26,27} The 100 patients in this trial received an average of 3.5 treatments per year. An intention-to-treat analysis at 12 months showed a decrease in average pain scores from 7.9 at baseline to 3.2 in the bupivacaine group, and from 7.8 to 3.1 in the bupivacaine plus steroid group. At least 50% improvement in the ODI score was observed in 80% and 84% of participants, respectively. In both groups, 90% of participants showed significant pain relief ($\geq 50\%$) at 12 months. The average relief per procedure was 16 weeks for bupivacaine and 14 weeks for bupivacaine plus betamethasone. There was no significant change in the intake of opioids. Efficacy remained the same at a 2-year follow-up, with 80% of patients in the bupivacaine group and 84% of patients in the bupivacaine plus steroid group continuing to show improvements of 50% or more in ODI scores. The average number of procedures over the 2 years was 5.6 for bupivacaine and 6.2 for bupivacaine plus steroids.

ALTERNATIVE METHODS

Pulsed Radiofrequency Facet Denervation

Moussa et al (2020) evaluated pulsed RF in patients diagnosed with chronic lower back pain of facet origin.²⁸ Patients were randomized into 3 groups: percutaneous pulsed RF treatment of the dorsal root ganglia (n=50), percutaneous RF denervation of the medial dorsal branch (n=50), and a control group that didn't receive any RF treatment (n=50). By 3 months post procedure, the pulsed RF group had better incidence of VAS improvement when compared to the other 2 groups (p=.014). At 2 year follow-up, the pulsed RF group maintained significant VAS improvement (p=.041), and this continued to the end of the study duration at 3 years (p=.044). An important limitation of this study is the lack of a sham control group.

Pulsed RF denervation was compared with steroid injection in a randomized trial of 80 patients reported by Hashemi et al (2014).²⁹ The patients were selected based on a single medial branch block; outcomes included a numeric rating scale for pain, ODI, and analgesic intake assessment. Radiofrequency and steroid injection to the medial branch reduced pain to a similar extent at 6 weeks; however, pain relief with pulsed RF remained low at 6 months (from 7.4 at baseline to 2.4 at 6 months) but had returned to near baseline levels in the steroid group pain by 6 months.

Kroll et al (2008) compared the efficacy of continuous RF with pulsed RF in the treatment of lumbar facet syndrome in an RCT with 50 patients.³⁰ No significant differences in the relative percentage improvement were noted between groups in VAS (p=.46) or ODI (p=.35) scores.

Within the pulsed RF group, comparisons of the relative change over time for both VAS ($p=.21$) and ODI ($p=.61$) scores were not significant. However, within the continuous RF group, VAS ($p=.02$) and ODI ($p=.03$) score changes were significant. The trial concluded that, although there was no significant difference between continuous RF and pulsed RF in the long-term outcomes, there was greater improvement over time in the continuous RF group.

Van Zundert et al (2007) randomized 23 patients (of 256 screened) with chronic cervical radicular pain to pulsed RF or sham treatment.³¹ Success was defined as a 50% or more improvement in GPE score, 20% or more reduction in VAS score for pain, and reduced pain medication use measured 3 months after treatment. Eighty-two percent of patients in the treatment arm and 33% in the sham arm showed at least 50% improvement in GPE score ($p=.03$) and 82% in the treatment group and 27% in the sham group achieved at least 20% reduction in VAS pain score ($p=.02$).

In a study by Tekin et al (2007), patients were randomized 20 each to conventional RF, pulsed RF, or a control group (local anesthetic only). Outcome measures were pain measured on a VAS and the ODI.¹³ Mean VAS and ODI scores were lower in both treatment groups than in controls posttreatment; however, reductions in pain were maintained at 6- and 12-month follow-ups only in the conventional RF group. The number of patients not using analgesics and patient satisfaction were highest in the conventional RF group.

Laser Denervation

Iwatsuki et al (2007) reported on laser denervation to the dorsal surface of the facet capsule in 21 patients who had a positive response to a diagnostic medial branch block.³² One year after laser denervation, 17 (81%) patients experienced greater than 70% pain reduction. In 4 (19%) patients who had previously undergone spinal surgery, the response to laser denervation was unsuccessful.

Alcohol Ablation

Joo et al (2013) compared alcohol ablation with RFA in a randomized study of 40 patients with recurrent thoracolumbar facet joint pain following an initial successful RF neurotomy.³³ At a 24-month follow-up, 3 patients in the alcohol ablation group had recurring pain compared with 19 in the RF group. Median effective periods were 10.7 months (range, 5.4 to 24 months) for RF and 24 months (range, 16.8 to 24 months) for alcohol ablation. No significant complications were identified.

Facet Debridement

Haufe and Mork (2010) reported on endoscopic facet debridement in a series of 174 patients with cervical ($n=45$), thoracic ($n=15$), or lumbar ($n=114$) pain who had a successful response to a diagnostic medial branch nerve block.³⁴ Capsular tissue was removed under direct observation via laparoscopy, followed by electrocautery or holmium lasers to completely remove the capsular region. Treatment was given on a single occasion, with most patients requiring treatment of 4 joints. At a minimum of a 3-year follow-up, 77%, 73%, and 68% of patients with cervical, thoracic, or lumbar disease, respectively, showed 50% or more reduction in pain, measured by VAS.

Section Summary: Therapeutic Medial Branch Blocks and Alternative Methods of Denervation

For individuals who have facet joint pain who receive therapeutic medial nerve branch blocks or alternative methods of facet joint denervation, the evidence includes a systematic review, randomized trials without a sham control, and uncontrolled case series. Pulsed RF does not appear to be as effective as conventional RF denervation, and there is insufficient evidence to evaluate the efficacy of other methods of denervation (eg, alcohol, laser, cryodenervation) for facet joint pain or the effect of therapeutic medial branch blocks on facet joint pain.

SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Association of Neurological Surgeons and Congress of Neurological Surgeons

In 2014, the American Association of Neurological Surgeons and the Congress of Neurological Surgeons updated their joint guidelines on the treatment of degenerative disease of the lumbar spine.³⁵ The 2 groups provided grade B recommendations: (1) intra-articular injections of lumbar facet joints were not suggested for the treatment of facet-mediated chronic low back pain; (2) medial nerve blocks were suggested for the short-term relief of facet-mediated chronic low back pain; and (3) lumbar medial nerve ablation was suggested for the short-term (3- to 6-month) relief of facet-mediated pain in patients who have chronic lower back pain without radiculopathy from degenerative disease of the lumbar spine.

American Society of Interventional Pain Physicians

In 2020, the American Society of Interventional Pain Physicians published guidelines on use of facet joint interventions for management of chronic spinal pain.³⁶ Use of facet joint nerve blocks for diagnosis of facet joint pain is recommended with a moderate to strong strength of recommendation for the lumbar spine (evidence level I to II), moderate strength for the cervical spine (evidence level II), and moderate strength for the thoracic spine (evidence level II); a criterion standard of $\geq 80\%$ pain relief was included for these recommendations. Radiofrequency ablation (RFA) is recommended for treatment of pain in the lumbar spine (moderate strength recommendation; evidence level II), cervical spine (moderate strength recommendation; evidence level II), and thoracic spine (weak to moderate strength recommendation; evidence level III). Facet joint nerve blocks are recommended for treatment of pain in the lumbar spine (moderate strength recommendation; evidence level II), cervical spine (moderate strength recommendation; evidence level II), and thoracic spine (weak to moderate strength recommendation; evidence level III). Treatment of facet joint pain with intraarticular injections is a weak strength recommendation with lower levels of evidence (level III, IV, and V evidence for the thoracic, lumbar, and cervical spine respectively).

American Society of Regional Anesthesia & Pain Medicine, et al.

International consensus guidelines published by the American Society of Regional Anesthesia & Pain Medicine and including 13 different pain societies (2020) provide recommendations regarding interventions for lumbar facet joint pain specifically.³⁷ When used for diagnosis, the guidelines suggest that intra-articular injections are more diagnostic than medial branch blocks (MBB), but note that intra-articular injections have a high technical failure rate and provide less predictive value when administered prior to RFA (grade B evidence, low level of certainty). For therapeutic treatment of lumbar facet pain the guideline recommends against use of medial branch blocks or intra-articular injections (grade D evidence, moderate level of certainty), although acknowledges certain clinical scenarios which may warrant these techniques, such as a contraindication to RFA.

Similarly, 18 pain societies created consensus guidelines on interventions for cervical spine joint pain (2022).³⁸ The group states, "Medial branch RFA is considered to be a definitive durable analgesic treatment for patients with neck pain arising from the cervical facet joints." They also state, "...MBB meet most criteria as a diagnostic intervention for cervical joint-mediated pain...."

The World Federation of Neurosurgical Societies Spine Committee

The World Federation of Neurosurgical Societies Spine Committee (2020) released recommendations on the treatment of and pain relief techniques in patients with lumbar spinal stenosis.³⁹ Statements that reached a positive committee consensus regarding facet joint pain are listed below.

- "Statement 10: Facet joint injections provide a useful diagnostic tool for LBP [lower back pain]."

National Institute for Health and Care Excellence

In 2016, the U.K. National Institute for Health and Care Excellence (NICE) published guidance on the assessment and management of low back pain and sciatica in those over 16 years of age.⁴⁰ NICE recommended that radiofrequency (RF) denervation can be considered for patients with chronic low back pain when "non-surgical treatment has not worked for them and the main source of pain is thought to come from structures supplied by the medial branch nerve and they have moderate or severe levels of localized back pain." Radiofrequency denervation should only be performed "after a positive response to a diagnostic medial branch block." The NICE cautioned that the length of pain relief after RF denervation is uncertain, and that results from repeat RF denervation procedures are also uncertain.

North American Spine Society Guideline

In 2020, the North American Spine Society (NASS) published guidance on the diagnosis and management of nonspecific low back pain in those 18 years of age and older.⁴¹ NASS recommends that in facet joint procedures, for patients responsive to a single diagnostic intra-articular injection with 50% relief, it is suggested that intra-articular steroids will provide no clinically meaningful improvement at 6 months (grade B level of evidence; fair evidence). Additionally, in these patients, there is insufficient evidence to recommend for or against using radiofrequency neurotomy or periarthicular phenol injections (grade I, insufficient or conflicting evidence). There is insufficient evidence for or against the use of single-photon emission computerized tomography (SPECT) imaging or the use of uncontrolled medial branch blocks versus pericapsular blocks for the diagnosis of zygapophyseal joint pain (both grade 1, insufficient or conflicting evidence). There is insufficient evidence to recommend for or against

using a 50% pain reduction following medial branch blockade to diagnose zygapophyseal joint pain (grade 1, insufficient or conflicting evidence). The use of cryodenervation has insufficient evidence for the treatment of zygapophyseal joint pain (grade I, insufficient or conflicting evidence); however, thermal radiofrequency ablation is suggested for patients with zygapophyseal joint low back pain, with relief durable for at least 6 months following the procedure (grade B, fair evidence). Cooled radiofrequency ablation of sacral lateral branch nerves and the dorsal ramus of L5 can be considered for sacroiliac joint pain diagnosed by dual blocks (grade C, poor quality evidence).

U.S. Preventive Services Task Force Recommendations

Not applicable.

Ongoing and Unpublished Clinical Trials

Currently, ongoing trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT03066960	Long Term Efficacy of Radiofrequency Neurotomy for Chronic Zygapophysial (Facet) Joint Related Neck Pain	34	Dec 2025
NCT05952518	Evaluation of Peripheral Nerve Stimulation as an Alternative to Radiofrequency Ablation for Facet Joint Pain	70	Oct 2027
Unpublished			
NCT02073292	A Randomized Controlled Trial Comparing Thermal and Cooled Radiofrequency Ablation Techniques of Thoracic Facets' Medial Branches to Manage Thoracic Pain	16	Dec 2022

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.

Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.

CPT/HCPCS	
64490	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level
64491	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure)
64492	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)
64493	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level
64494	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)
64495	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint
64634	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure)
64635	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint

64636	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)
64999	Unlisted procedure, nervous system

REVISIONS	
02-08-2010	The Facet Joint Denervation medical policy is a new freestanding policy developed from the Minimally Invasive Procedures for Spine Pain medical policy which was effective October 18, 2004. The Minimally Invasive Procedures for Spine Pain is no longer an active medical policy.
04-04-2011	Description section updated
	Policy Guidelines section added
	Rationale section updated
	In Coding section: ▪ Updated wording for 77003
	References section updated
01-01-2012	In Coding section: ▪ Removed CPT Codes: 64622, 64623, 64626, 64627 ▪ Added CPT Codes: 64633, 64634, 64635, 64636
12-02-2013	Revised Title from "Facet Joint Denervation" to "Facet Joint Denervation (Cervical and Lumbar)
	Description section updated
	In Policy section: ▪ Revised A from "Facet joint denervation (percutaneous radiofrequency facet denervation, percutaneous radiofrequency facet ablation, facet rhizotomy, facet thermocoagulation) of cervical facet joints (C3-4 and below) and lumbar facet joints is considered medically necessary when ALL of the following criteria are met:" to "Non-pulsed radiofrequency denervation of cervical facet joints (C3-4 and below) and lumbar facet joints is considered medically necessary when ALL of the following criteria are met:" ▪ Added to Item A 2 "disabling" to read "Disabling low back (lumbosacral) or neck (cervical) pain, suggestive of facet joint origin as evidenced by absence of nerve root compression as documented in the medical record on history, physical and radiographic evaluations; and the pain is not radicular" ▪ Revised Item A 4 from "A trial of controlled diagnostic medial branch blocks (See Policy Guidelines) under fluoroscopic guidance has resulted in at least a 50% reduction in pain; "to "There has been a successful trial of controlled medial branch blocks (See Policy Guidelines)" ▪ Revised Item B from, "Facet joint denervation (percutaneous Radiofrequency facet denervation, percutaneous radiofrequency facet ablation, facet rhizotomy, facet thermocoagulation) is considered experimental / investigational for the treatment of chronic spinal / back pain for all uses that do not meet the criteria listed above, including but not limited to treatment of thoracic facet or sacroiliac (SI) joint pain." to "Radiofrequency denervation is considered experimental / investigational for the treatment of chronic spinal / back pain for all uses that do not meet the criteria listed above, including but not limited to treatment of thoracic facet joint pain." ▪ Revised Item C from, "Pulsed radiofrequency denervation is considered experimental / investigational for the treatment of chronic spinal / back pain." to "All other methods of denervation are considered experimental / investigational for the treatment of chronic spinal / back pain, including, but not limited to pulsed radiofrequency

REVISIONS	
	<p>denervation, laser denervation, chemodenervation (e.g., alcohol, phenol, or high-concentration local anesthetics), and cryodenervation."</p> <ul style="list-style-type: none"> ▪ Added Item D, "Therapeutic medial branch blocks are considered experimental / investigational." ▪ Added Item E, "If there has been a prior successful radiofrequency (RF) denervation, additional diagnostic medial branch blocks for the same level of the spine are not medically necessary." <p>In Policy Guidelines: Revised from, "The diagnostic blocks should involve the levels being considered for RF treatment. These diagnostic blocks should be targeted to the likely pain generator. Single level blocks lead to more precise diagnostic information, but multiple single level blocks require several visits and additional exposure to radiation." to, "A successful trial of controlled diagnostic medial branch blocks consists of:</p> <ol style="list-style-type: none"> 1. 2 separate positive blocks on different days with local anesthetic only (no steroids or other drugs), or 2. a placebo controlled series of blocks, under fluoroscopic guidance, that has resulted in at least a 50% reduction in pain for the duration of the local anesthetic used (e.g., 3 hours longer with bupivacaine than lidocaine). <p>No therapeutic intra-articular injections (i.e., steroids, saline, or other substances) should be administered for a period of at least 4 weeks prior to the diagnostic medial branch block. The diagnostic blocks should involve the levels being considered for RF treatment and should not be conducted under intravenous sedation unless specifically indicated (e.g., the patient is unable to cooperate with the procedure). These diagnostic blocks should be targeted to the likely pain generator. Single level blocks lead to more precise diagnostic information, but multiple single level blocks require several visits and additional exposure to radiation."</p> <p>Rationale section updated</p> <p>In Coding section:</p> <ul style="list-style-type: none"> ▪ Nomenclature updated on CPT codes: 64636, 77003 ▪ Nomenclature updated on ICD-9 codes: 722.82, 722.83 ▪ Removed ICD-9 codes: 721.2, 721.41, 722.82, 724.1 ▪ ICD-10 Codes added <p>Referenced updated</p>
04-30-2015	<p>In Policy section:</p> <ul style="list-style-type: none"> ▪ In Item A revised "Non-pulsed-radiofrequency" to read "Thermal radiofrequency denervation..." ▪ In Item A revised "C3-4 and below" to "C2-3 and below" to read "...cervical facet joints (C 2-3 and below) and lumbar facet joint..." ▪ In Item A 1 revised "No prior spinal fusion surgery" to read "No prior posterior spinal fusion..." ▪ In Item A 2 revised "Disabling low back (lumbosacral) or neck (cervical) pain, suggestive of facet joint origin as evidenced by absence of nerve root compression as documented in the medical record on history, physical, and radiographic evaluations; and the pain is not radicular" to read "Disabling low back (lumbosacral) or neck (cervical) pain, suggestive of intrinsic facet joint origin as supported by history and physical". ▪ In Item A 3 revised "Pain has failed to respond to three (3) months of conservative management which may consist of therapies such as nonsteroidal anti-inflammatory medications, acetaminophen, manipulation, physical therapy, and a home exercise program" to read "Pain has failed to respond to three (3) months of conservative management".

REVISIONS	
	<ul style="list-style-type: none"> ▪ In Item A 4 revised "There has been a successful trial of controlled medial branch blocks (See Policy Guidelines)" to read "There has been a successful trial of confirming medial branch blocks (See Policy Guidelines)". ▪ In Item A 5 revised "If there has been a prior successful radiofrequency (RF) denervation, a minimum time of six (6) months has elapsed since prior RF treatment (per side, per anatomical level of the spine)." to read "If there has been a prior successful radiofrequency (RF) denervation, a minimum time of six (6) months has elapsed since prior RF nerve treatment" ▪ In Policy Guideline 2 revised "series of blocks," to "series of dual confirming blocks" and "50% reduction in pain" to "80% reduction in pain" to read, "a placebo controlled series of dual confirming blocks, under fluoroscopic guidance, that has resulted in at least an 80% reduction in pain..."
01-07-2016	Updated Description section.
	In Policy section:
	<ul style="list-style-type: none"> ▪ Added Item 3 to Policy Guidelines.
	Updated Rationale section.
	In Coding section:
	<ul style="list-style-type: none"> ▪ Removed CPT code 77003.
	Updated References section.
10-01-2016	In Policy section:
	<ul style="list-style-type: none"> ▪ In Item E, removed "diagnostic medial branch blocks for the same level of the spine are not medically necessary" and added "prognostic blocks at the same level may be considered medically necessary to confirm the source of pain is from the same segmental level" to read, "If there has been a prior successful radiofrequency (RF) denervation, additional prognostic blocks at the same level may be considered medically necessary to confirm the source of pain is from the same segmental level." ▪ In Policy Guidelines, removed "a) 2 separate positive blocks on different days with local anesthetic only (no steroids or other drugs), or b) a placebo controlled series of dual confirming" and added "two positive", "performed on separate days", and "(no steroids or other drugs)" to read, "A successful trial of controlled diagnostic medial branch blocks consists of 2 positive blocks performed on separate days, under fluoroscopic guidance, that have resulted in at least an 80% reduction in pain for the duration of the local anesthetic (no steroids or other drugs) used (e.g., 3 hours longer with bupivacaine than lidocaine)."
	Updated References section.
01-30-2018	Revised Policy title from "Facet Joint Denervation (Cervical and Lumbar)."
	Updated Description section.
	Updated Rationale section.
	In Coding section:
	<ul style="list-style-type: none"> ▪ Removed ICD-9 codes.
	Updated References section.
06-11-2018	Policy published to the bcbsks.com website on 05-09-2018 with an effective date of 06-11-2018.
	In Coding section:
	<ul style="list-style-type: none"> ▪ Added ICD-10 codes: M43.04, M43.14, M46.84, M46.94, M47.14, M47.24, M47.814, M47.894, M48.04, M54.14, M54.6.
01-04-2019	Updated Description section.
	Updated Rationale section.
	In Coding section:
	<ul style="list-style-type: none"> ▪ Removed coding bullets.
	Updated References section.

REVISIONS	
08-21-2020	Updated Description Section
	Policy section: Removed Thermal radiofrequency Added Nonpulsed radiofrequency
	Updated Rationale section
	In Coding section: <ul style="list-style-type: none"> CPT added code: 64625 ICD 10 removed codes: M43.02, M43.04, M43.06, M43.12, M43.14, M43.16, M46.84, M46.94, M48.04
	Updated Reference Section
01-15-2021	In policy section B- <ul style="list-style-type: none"> Added....., or nerves innervating the SI joint. No other updates at this time.
10-01- 2021	In Coding section: (Effective 10-01-2021) <ul style="list-style-type: none"> Deleted ICD-10 code M54.5 Added ICD-10 codes M54.50; M54.51; M54.59
02-10-2022	Update Description Section
	Updated Coding Section <ul style="list-style-type: none"> ICD 10 codes converted to code ranges Removed ICD-10 codes: M43.02, M43.04, M43.06, M43.12, M43.14, M43.16, M46.84, M46.94, M48.04
	Update Rationale Section
	Update References Section
12-29-2022	Update Description Section
	Update Rationale Section
	Update References Section
01-05-2024	Updated Description Section
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> Added 64490, 64491, 64492, 64493, 64494, 64495 Removed ICD-10 Codes
	Updated References Section
12-23-2024	Update Description Section
	Update Rationale Section
	Update References Section
01-05-2026	Updated Description Section
	Updated Rationale Section
	Updated Reference Section

REFERENCES

1. Boswell MV, Manchikanti L, Kaye AD, et al. A Best-Evidence Systematic Appraisal of the Diagnostic Accuracy and Utility of Facet (Zygapophysial) Joint Injections in Chronic Spinal Pain. *Pain Physician*. 2015; 18(4): E497-533. PMID 26218947
2. Falco FJ, Datta S, Manchikanti L, et al. An updated review of the diagnostic utility of cervical facet joint injections. *Pain Physician*. 2012; 15(6): E807-38. PMID 23159977
3. Falco FJ, Manchikanti L, Datta S, et al. Systematic review of the therapeutic effectiveness of cervical facet joint interventions: an update. *Pain Physician*. 2012; 15(6): E839-68. PMID 23159978

4. Falco FJ, Manchikanti L, Datta S, et al. An update of the effectiveness of therapeutic lumbar facet joint interventions. *Pain Physician*. 2012; 15(6): E909-53. PMID 23159980
5. Falco FJ, Manchikanti L, Datta S, et al. An update of the systematic assessment of the diagnostic accuracy of lumbar facet joint nerve blocks. *Pain Physician*. 2012; 15(6): E869-907. PMID 23159979
6. Cohen SP, Strassels SA, Kurihara C, et al. Randomized study assessing the accuracy of cervical facet joint nerve (medial branch) blocks using different injectate volumes. *Anesthesiology*. Jan 2010; 112(1): 144-52. PMID 19996954
7. Cohen SP, Stojanovic MP, Crooks M, et al. Lumbar zygapophysial (facet) joint radiofrequency denervation success as a function of pain relief during diagnostic medial branch blocks: a multicenter analysis. *Spine J*. 2008; 8(3): 498-504. PMID 17662665
8. Pampati S, Cash KA, Manchikanti L. Accuracy of diagnostic lumbar facet joint nerve blocks: a 2-year follow-up of 152 patients diagnosed with controlled diagnostic blocks. *Pain Physician*. 2009; 12(5): 855-66. PMID 19787011
9. Manchikanti L, Pampati S, Cash KA. Making sense of the accuracy of diagnostic lumbar facet joint nerve blocks: an assessment of the implications of 50% relief, 80% relief, single block, or controlled diagnostic blocks. *Pain Physician*. 2010; 13(2): 133-43. PMID 20309379
10. Li H, An J, Zhang J, et al. Comparative efficacy of radiofrequency denervation in chronic low back pain: A systematic review and network meta-analysis. *Front Surg*. 2022; 9: 899538. PMID 35990102
11. Janapala RN, Manchikanti L, Sanapati MR, et al. Efficacy of Radiofrequency Neurotomy in Chronic Low Back Pain: A Systematic Review and Meta-Analysis. *J Pain Res*. 2021; 14: 2859-2891. PMID 34531682
12. Nath S, Nath CA, Pettersson K. Percutaneous lumbar zygapophysial (Facet) joint neurotomy using radiofrequency current, in the management of chronic low back pain: a randomized double-blind trial. *Spine (Phila Pa 1976)*. May 20 2008; 33(12): 1291-7; discussion 1298. PMID 18496338
13. Tekin I, Mirzai H, Ok G, et al. A comparison of conventional and pulsed radiofrequency denervation in the treatment of chronic facet joint pain. *Clin J Pain*. 2007; 23(6): 524-9. PMID 17575493
14. van Wijk RM, Geurts JW, Wynne HJ, et al. Radiofrequency denervation of lumbar facet joints in the treatment of chronic low back pain: a randomized, double-blind, sham lesion-controlled trial. *Clin J Pain*. 2005; 21(4): 335-44. PMID 15951652
15. Lakemeier S, Lind M, Schultz W, et al. A comparison of intraarticular lumbar facet joint steroid injections and lumbar facet joint radiofrequency denervation in the treatment of low back pain: a randomized, controlled, double-blind trial. *Anesth Analg*. Jul 2013; 117(1): 228-35. PMID 23632051
16. Manchikanti L, Kaye AD, Boswell MV, et al. A Systematic Review and Best Evidence Synthesis of the Effectiveness of Therapeutic Facet Joint Interventions in Managing Chronic Spinal Pain. *Pain Physician*. 2015; 18(4): E535-82. PMID 26218948
17. Civelek E, Cansever T, Kabatas S, et al. Comparison of effectiveness of facet joint injection and radiofrequency denervation in chronic low back pain. *Turk Neurosurg*. 2012; 22(2): 200-6. PMID 22437295
18. Lord SM, Barnsley L, Wallis BJ, et al. Percutaneous radio-frequency neurotomy for chronic cervical zygapophyseal-joint pain. *N Engl J Med*. Dec 05 1996; 335(23): 1721-6. PMID 8929263

19. van Eerd M, de Meij N, Kessels A, et al. Efficacy and Long-term Effect of Radiofrequency Denervation in Patients with Clinically Diagnosed Cervical Facet Joint Pain: A Double-blind Randomized Controlled Trial. *Spine (Phila Pa 1976)*. Mar 01 2021; 46(5): 285-293. PMID 33534439
20. Husted DS, Orton D, Schofferman J, et al. Effectiveness of repeated radiofrequency neurotomy for cervical facet joint pain. *J Spinal Disord Tech*. Aug 2008; 21(6): 406-8. PMID 18679094
21. Schofferman J, Kine G. Effectiveness of repeated radiofrequency neurotomy for lumbar facet pain. *Spine (Phila Pa 1976)*. Nov 01 2004; 29(21): 2471-3. PMID 15507813
22. Smuck M, Crisostomo RA, Trivedi K, et al. Success of initial and repeated medial branch neurotomy for zygapophysial joint pain: a systematic review. *PM R*. Sep 2012; 4(9): 686-92. PMID 22980421
23. Rambaransingh B, Stanford G, Burnham R. The effect of repeated zygapophysial joint radiofrequency neurotomy on pain, disability, and improvement duration. *Pain Med*. Sep 2010; 11(9): 1343-7. PMID 20667024
24. Manchikanti L, Singh V, Falco FJ, et al. Comparative outcomes of a 2-year follow-up of cervical medial branch blocks in management of chronic neck pain: a randomized, double-blind controlled trial. *Pain Physician*. 2010; 13(5): 437-50. PMID 20859313
25. Manchikanti L, Singh V, Falco FJ, et al. Evaluation of lumbar facet joint nerve blocks in managing chronic low back pain: a randomized, double-blind, controlled trial with a 2-year follow-up. *Int J Med Sci*. May 28 2010; 7(3): 124-35. PMID 20567613
26. Manchikanti L, Singh V, Falco FJ, et al. Comparative effectiveness of a one-year follow-up of thoracic medial branch blocks in management of chronic thoracic pain: a randomized, double-blind active controlled trial. *Pain Physician*. 2010; 13(6): 535-48. PMID 21102966
27. Manchikanti L, Singh V, Falco FJ, et al. The role of thoracic medial branch blocks in managing chronic mid and upper back pain: a randomized, double-blind, active-control trial with a 2-year followup. *Anesthesiol Res Pract*. 2012; 2012: 585806. PMID 22851967
28. Moussa WM, Khedr W, Elsayy M. Percutaneous pulsed radiofrequency treatment of dorsal root ganglion for treatment of lumbar facet syndrome. *Clin Neurol Neurosurg*. Dec 2020; 199: 106253. PMID 33045627
29. Hashemi M, Hashemian M, Mohajerani SA, et al. Effect of pulsed radiofrequency in treatment of facet-joint origin back pain in patients with degenerative spondylolisthesis. *Eur Spine J*. Sep 2014; 23(9): 1927-32. PMID 24997616
30. Kroll HR, Kim D, Danic MJ, et al. A randomized, double-blind, prospective study comparing the efficacy of continuous versus pulsed radiofrequency in the treatment of lumbar facet syndrome. *J Clin Anesth*. Nov 2008; 20(7): 534-7. PMID 19041042
31. Van Zundert J, Patijn J, Kessels A, et al. Pulsed radiofrequency adjacent to the cervical dorsal root ganglion in chronic cervical radicular pain: a double blind sham controlled randomized clinical trial. *Pain*. Jan 2007; 127(1-2): 173-82. PMID 17055165
32. Iwatsuki K, Yoshimine T, Awazu K. Alternative denervation using laser irradiation in lumbar facet syndrome. *Lasers Surg Med*. Mar 2007; 39(3): 225-9. PMID 17345622
33. Joo YC, Park JY, Kim KH. Comparison of alcohol ablation with repeated thermal radiofrequency ablation in medial branch neurotomy for the treatment of recurrent thoracolumbar facet joint pain. *J Anesth*. Jun 2013; 27(3): 390-5. PMID 23192698
34. Haufe SM, Mork AR. Endoscopic facet debridement for the treatment of facet arthritic pain--a novel new technique. *Int J Med Sci*. May 25 2010; 7(3): 120-3. PMID 20567612
35. Watters WC, Resnick DK, Eck JC, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: injection therapies,

- low-back pain, and lumbar fusion. *J Neurosurg Spine*. Jul 2014; 21(1): 79-90. PMID 24980590
36. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive Evidence-Based Guidelines for Facet Joint Interventions in the Management of Chronic Spinal Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines Facet Joint Interventions 2020 Guidelines. *Pain Physician*. May 2020; 23(3S): S1-S127. PMID 32503359
 37. Cohen SP, Bhaskar A, Bhatia A, et al. Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group. *Reg Anesth Pain Med*. Jun 2020; 45(6): 424-467. PMID 32245841
 38. Hurley RW, Adams MCB, Barad M, et al. Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group. *Reg Anesth Pain Med*. Jan 2022; 47(1): 3-59. PMID 34764220
 39. Fornari M, Robertson SC, Pereira P, et al. Conservative Treatment and Percutaneous Pain Relief Techniques in Patients with Lumbar Spinal Stenosis: WFNS Spine Committee Recommendations. *World Neurosurg* X. Jul 2020; 7: 100079. PMID 32613192
 40. National Institute for Health and Clinical Excellence (NICE). NICE guideline [NG59]: Low back pain and sciatica in over 16s: assessment and management. 2016. Updated 2020; <https://www.nice.org.uk/guidance/NG59>. Accessed October 3, 2025.
 41. Evidence Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis and Treatment of Low Back Pain. American Spine Society. <https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf>. Published 2020. Accessed October 2, 2025.

OTHER REFERENCES

1. Blue Cross and Blue Shield of Kansas Anesthesiology Liaison Committee, May 2014; May 2015; July 2016; January 2017, May 2021.